1. Home
  2. NOMA vs LUNG Comparison

NOMA vs LUNG Comparison

Compare NOMA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOMADAR Corp.

NOMA

NOMADAR Corp.

HOLD

Current Price

$3.09

Market Cap

59.1M

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.27

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOMA
LUNG
Founded
2023
1995
Country
United States
United States
Employees
8
N/A
Industry
Services-Misc. Amusement & Recreation
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.1M
57.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NOMA
LUNG
Price
$3.09
$1.27
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
5.5K
250.8K
Earning Date
05-22-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$2.55
$1.13
52 Week High
$10.00
$3.39

Technical Indicators

Market Signals
Indicator
NOMA
LUNG
Relative Strength Index (RSI) 52.82 43.82
Support Level $3.05 $1.20
Resistance Level $3.95 $1.65
Average True Range (ATR) 0.24 0.09
MACD 0.01 -0.02
Stochastic Oscillator 79.70 21.84

Price Performance

Historical Comparison
NOMA
LUNG

About NOMA NOMADAR Corp.

Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: